The Latest Cardiac and Vascular News
NEW YORK–(BUSINESS WIRE)–Ninety One, Inc., an augmented intelligence company developing innovative software and data science solutions designed to automate cardiac remote monitoring and further Precision Medicine, announced today, announced today that Dr. Thomas Hong will be the first in the state of Texas to utilize the technology that combines state-of-the-art […]
EAST HANOVER, N.J., March 28, 2020 /PRNewswire/ — Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was presented during a Late Breaker session at the American College of […]
Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV THOUSAND OAKS, Calif., March 28, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human […]
TARRYTOWN, N.Y., March 30, 2020 /PRNewswire/ — Results from separate positive Phase 3 trial of Praluent® (alirocumab) in patients with HoFH also presented; FDA regulatory submission planned for Q2 2020 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase 3 results of evinacumab were presented today as a late-breaking presentation at the American College of […]
Serum EPA Levels Showed Approximately 400% Increase Following Administration of VASCEPA High EPA Levels Associated with Substantial Reductions in Multiple Cardiovascular Endpoints Including Heart Failure and Total Mortality Amarin to Webcast Discussion of Presented Data March 30, 5:30 – 6:30 p.m., Eastern Time DUBLIN, Ireland and BRIDGEWATER, N.J., March 30, […]
Top-line Results for GALACTIC-HF Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., March 30, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, were published during the […]
BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients undergoing complex percutaneous coronary intervention WILMINGTON, Del.–(BUSINESS WIRE)–Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) […]
LOS ANGELES–(BUSINESS WIRE)–QT Medical, a MedTech company focusing on cardiac care with personal electrocardiogram (ECG), announced today a limited time offer of $30 per ECG test to skilled nursing facilities (SNFs) and telehealth services. The ECG tests will be performed using PCA 500, a complete 12-lead ECG platform that includes a super-compact recorder, […]
New data showed consistent effect of FARXIGA in patients with heart failure with reduced ejection fraction, regardless of background therapy WILMINGTON, Del.–(BUSINESS WIRE)–New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of […]
Bempedoic acid is being developed as a first-in-class, affordable, oral treatment which lowers low-density lipoprotein cholesterol (LDL-C), and which can be combined with other oral treatments to help lower cholesterol even further1,2,3,4,5 Data from Phase 2 study show a 40% reduction in LDL-C for patients with type 2 diabetes who […]
